TuHURA Biosciences to Acquire Kineta’s KVA12123 for Treating Solid Tumors
Shots:
- TuHURA has signed an exclusivity & right of first offer agreement with Kineta to acquire the latter’s KVA12123 with its global patent rights & applications, product & development program assets as well as technical & business information
- Kineta will receive $5M, with $2.5M at signing & another $2.5M by Jul 15, 2024. TuHURA further sold $5M as equity in a private offering to an existing shareholder; the agreement's exclusivity period lasts 90 days, extendable by 20 days
- KVA12123 (BIW) is an anti-VISTA Ab CPI that alters the tumor microenvironment by reversing VISTA immune suppression, overcoming resistance to immunotherapies; currently under P-I/II study alone & combined with Keytruda for advanced solid tumors (results anticipated in Q4'24)
Ref: TuHURA Biosciences | Image: TuHURA Biosciences
Related News: Yumanity Signs a Purchase Agreement with Janssen for YTX-7739 & Reverse Merged with Kineta to Advance KVA12.1
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
